Earnings Results to Track: Nektar Therapeutics (NASDAQ: NKTR)

On Thursday, Shares of Nektar Therapeutics (NASDAQ: NKTR) showed the bearish trend with a lower momentum of -1.19% to $31.64. The company traded total volume of 1,341,133 shares as contrast to its average volume of 1.66M shares. The company has a market value of $5.48B and about 173.31M shares outstanding.

Nektar Therapeutics (NKTR) recently stated financial results for the fourth quarter and full year ended December 31, 2018.

Cash and investments in marketable securities at December 31, 2018 were $1.90B as contrast to $353.20M at December 31, 2017.

Summary of Financial Results:

Revenue for the fourth quarter of 2018 was $39.80M as contrast to $95.50M in the fourth quarter of 2017. Revenue in the fourth quarter of 2017 included a total of $60.00M of non-recurring revenue related to a new sublicense agreement, a contract settlement agreement and the recognition of deferred revenue from several partnership agreements. Revenue for the year ended December 31, 2018 was $1.20B as contrast to $307.70M in 2017 and included the recognition of $1.060B of license revenue from the Bristol-Myers Squibb partnership agreement.

Total operating costs and expenses in the fourth quarter of 2018 were $140.10M as contrast to $119.50M in the fourth quarter of 2017. Total operating costs and expenses for 2018 were $505.40M as contrast to $367.40M in 2017. Total operating costs and expenses increased mainly as a result of increased research and development (R&D) expense.

R&D expense in the fourth quarter of 2018 was $108.90M as contrast to $81.40Mfor the fourth quarter of 2017. R&D expense for the year ended December 31, 2018 was $399.50M as contrast to $268.50M in 2017. R&D expense was higher in the fourth quarter and full year 2018 as contrast to the same periods in 2017 mainly because of expenses for our pipeline programs, counting the continued development of bempegaldesleukin in Phase 2 and registrational studies and related manufacturing costs, costs related to the NKTR-181 New Drug Application and NKTR-181 pre-commercial manufacturing, Phase 1 clinical studies of NKTR-358, the Phase 1 study of NKTR-262 in combination with bempegaldesleukin and IND-enabling activities for NKTR-255.

General and administrative (G&A) expense was $23.80M in the fourth quarter of 2018 as contrast to $12.30M in the fourth quarter of 2017. G&A expense for 2018 was $81.40M as contrast to $52.40M in 2017. G&A expense was higher in the fourth quarter and full year 2018 as contrast to the same periods in 2017 mainly because of a boost in non-cash stock-based compensation expense.

Net loss for the fourth quarter of 2018 was $98.20M or $0.57 basic and diluted loss per share as contrast to a net loss of $33.80M or $0.21 basic and diluted loss per share in the fourth quarter of 2017. Net income for the year ended December 31, 2018was $681.30M or $3.78 diluted earnings per share as contrast to a net loss of $96.70M or $0.62 basic and diluted loss per share in 2017.

The Company offered net profit margin of 57.10% while its gross profit margin was 98.00%. ROE was recorded as 50.20% while beta factor was 2.97. The stock, as of recent close, has shown the weekly upbeat performance of 1.64% which was maintained at -3.74% in this year.



Anna Abbott

Anna Abbott

I am Anna Abbott and I give “Digital Wall” an insight into the most recent news hitting the “Entertainment” sector . I have been an independent PR adviser for over 11 years in the city and in recent years turned my experience in music and passion for journalism into a full time role. Address: 661 Station Street, Fremont, CA 94536, USA Phone: (+1) 510-936-8074 Email: anna.abbott@yourdigitalwall.com